title: Severe VA/Q mismatch in perfused lungs evoked by sequential challenge with endotoxin and E. coli hemolysin.
abstract: Escherichia coli hemolysin (ECH), an important pathogenicity factor in extraintestinal E. coli infections, provokes pulmonary hypertension and microvascular leakage in buffer-perfused rabbit lungs. We investigated gas exchange abnormalities in response to low doses of ECH, lipopolysaccharides (LPS), and sequential and combined application of these bacterial agents by using the multiple inert gas elimination technique. In control lungs and after admixture of 100 ng/ml of LPS, unimodal narrow distribution of perfusion and ventilation to midrange ventilation-perfusion (VA/Q) areas was noted. ECH [0.08 hemolytic units (HU)/ml] caused a moderate increase in pulmonary arterial pressure (< 10 mmHg), progressive lung edema formation (approximately 10 g within 20 min), and a broadening of perfusate and gas flow dispersion. Application of 0.08 HU/ml of ECH in lungs "primed" with 100 ng/ml of LPS in a preceding 125-min perfusion period provoked a large increase in pulmonary arterial pressure (> 50 mmHg within 5 min), rapid edema formation (approximately 10 g within 10 min), and severe VA/Q mismatch with predominance of shunt flow. Vasoconstrictor response and VA/Q mismatch, but not edema formation, were largely inhibited by pretreatment of lungs with acetylsalicylic acid or the thromboxane receptor antagonist BM-13.505. In addition, "rescue" application of BM-13.505 rapidly reversed pressure rise and shunt flow due to sequential LPS and/or ECH stimulation, whereas edema formation was not affected. We conclude that the marked pulmonary hypertension in response to low doses of ECH in LPS-primed lungs is paralleled by severe gas exchange abnormalities with predominance of shunt flow. Both the vasoconstrictor response and the development of shunt are closely related to toxin-induced thromboxane generation.
authors.affiliation: Department of Internal Medicine, Justus-Liebig-University Giessen, Germany.
authors.forename: D
authors.initials: D
authors.lastname: Walmrath
authors.forename: J
authors.initials: J
authors.lastname: Pilch
authors.forename: M
authors.initials: M
authors.lastname: Scharmann
authors.forename: F
authors.initials: F
authors.lastname: Grimminger
authors.forename: W
authors.initials: W
authors.lastname: Seeger
mesh_terms: D000818:Animals; D001241:Aspirin / Q000494:pharmacology; D001426:Bacterial Proteins / Q000633:toxicity*; D029968:Escherichia coli Proteins; D005260:Female; D006460:Hemolysin Proteins / Q000633:toxicity*; D066298:In Vitro Techniques; D008070:Lipopolysaccharides / Q000633:toxicity*; D008168:Lung / Q000187:drug effects*; D008297:Male; D005741:Noble Gases; D010648:Phenylacetates / Q000494:pharmacology; D011652:Pulmonary Circulation / Q000187:drug effects; D011654:Pulmonary Edema / Q000139:chemically induced / Q000503:physiopathology; D011817:Rabbits; D012475:Salmonella / Q000378:metabolism*; D013449:Sulfonamides / Q000494:pharmacology; D013931:Thromboxanes / Q000037:antagonists & inhibitors; D014692:Ventilation-Perfusion Ratio / Q000187:drug effects*
chemical_list: D001426:Bacterial Proteins; D029968:Escherichia coli Proteins; D006460:Hemolysin Proteins; C036507:Hlya protein, E coli; D008070:Lipopolysaccharides; D005741:Noble Gases; D010648:Phenylacetates; D013449:Sulfonamides; D013931:Thromboxanes; D001241:Aspirin; C051762:daltroban